Page last updated: 2024-10-26

famotidine and Cardiomyopathies

famotidine has been researched along with Cardiomyopathies in 1 studies

Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).

Research Excerpts

ExcerptRelevanceReference
" Dexrazoxane is approved to combat the cardiotoxicity, but limited by its adverse effects."1.48Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model. ( Allakonda, L; Kondru, SK; Konduri, P; Potnuri, AG, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kondru, SK1
Potnuri, AG1
Allakonda, L1
Konduri, P1

Other Studies

1 other study available for famotidine and Cardiomyopathies

ArticleYear
Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model.
    Molecular and cellular biochemistry, 2018, Volume: 441, Issue:1-2

    Topics: Animals; Apoptosis; Cardiomyopathies; Doxorubicin; Famotidine; Histamine H2 Antagonists; Male; Muscl

2018